Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for intracellular diseases using proprietary endosomal escape vehicle (EEV) technology that enables efficient delivery of therapeutics across cell membranes and into target cells. The company's pipeline focuses on rare neuromuscular and inherited retinal diseases, with multiple exon-skipping candidates in development for Duchenne muscular dystrophy and related conditions, alongside a partnership program with Vertex Pharmaceuticals for myotonic dystrophy. Entrada currently generates no product revenues and is advancing candidates through clinical trials with the expectation of revenue only upon regulatory approval and successful commercialization, planning to retain commercial rights and build its own sales infrastructure focused on specialist physicians treating rare diseases.